☆ 4.6 Article

TP53 Gene 72 Arg/Pro (rs1042522) single nucleotide polymorphism increases the risk and the severity of chronic lymphocytic leukemia

FRONTIERS IN ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Haolan Wang et al.

Summary: The TP53 tumor suppressor gene is frequently altered in human cancers and has been extensively studied. The p53 protein, a transcription factor, plays critical roles in cell cycle regulation, apoptosis, and genomic stability. It also regulates cell metabolism, ferroptosis, tumor microenvironment, and autophagy, contributing to tumor suppression. TP53 mutations not only impair its tumor suppressor function, but also confer oncogenic properties to p53 mutants. Despite being an attractive target, p53 was considered undruggable until recently, and progress in p53-targeted therapies has been limited.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Add to Collection

Review Oncology

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

Francesca Perutelli et al.

Summary: Immune-based therapeutic strategies have revolutionized the treatment of hematological disorders by enhancing the immune response against tumor cells. However, individual use of immunotherapy has not shown optimal results in terms of disease control due to CLL-related immune dysfunctions. The understanding of the interactions between immune cells and tumor cells has led to the development of novel combination approaches that hold promise for future treatment of CLL.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments

Eric M. Granowicz et al.

Summary: TP53-mutated AML is a subgroup with the worst prognosis, and while the clinical applicability of treatment options remains uncertain, advancements in understanding AML genetics and biology have led to the emergence of novel treatment choices.

ONCOTARGETS AND THERAPY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children

Hanaa Skhoun et al.

Summary: The study finds a significant association between TP53 gene polymorphisms and genetic susceptibility to childhood acute lymphoblastic leukemia (ALL) in Morocco.

MOLECULAR BIOLOGY REPORTS (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children

Fan Liao et al.

Summary: This study investigated the association between TP53 rs1042522 C>G polymorphism and glioma risk in Chinese children. The results showed no significant association between the polymorphism and childhood glioma risk.

BIOMED RESEARCH INTERNATIONAL (2022)

Add to Collection

Article Genetics & Heredity

Association of Polymorphic Markers of the TP53, MDM2, and CDKN1A Genes with the Risk of Ovarian Cancer

P. K. Brenner et al.

Summary: This study analyzed the relationship between several gene polymorphic markers and ovarian cancer risk and found no association.

RUSSIAN JOURNAL OF GENETICS (2022)

Add to Collection

Article Hematology

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

Michael Hallek et al.

Summary: Chronic lymphocytic leukemia is a common type of leukemia in elderly patients, diagnosed through blood tests and immunophenotyping. Treatment is determined based on disease activity and stage, with different genetic and biological markers providing prognostic information.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Review Oncology

p53 signaling in cancer progression and therapy

Hany E. Marei et al.

Summary: The p53 protein, known as the guardian of the genome, plays a critical role in preserving genomic integrity, and mutations in the TP53 gene can lead to uncontrolled cell proliferation and cancer formation. With p53 deficiency being common in human cancer, restoring p53 function may be an effective approach for cancer treatment.

CANCER CELL INTERNATIONAL (2021)

Add to Collection

Article Genetics & Heredity

Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes

Bartosz Slominski et al.

Summary: The TP53 codon 72 polymorphism is associated with complications and comorbidities in patients with T1D. The Pro/Pro genotype is linked to an increased risk of microvascular complications, dyslipidemia, and celiac disease, while the Arg/Arg variant is associated with a decreased risk of autoimmune thyroiditis and celiac disease. The Pro allele is connected to an increased risk of dyslipidemia, autoimmune thyroiditis, and celiac disease.

JOURNAL OF MOLECULAR MEDICINE-JMM (2021)

Add to Collection

Review Oncology

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Matteo Molica et al.

Summary: TP53 is a key tumor suppressor gene with protean functions in maintaining genomic balance, and mutations are frequently observed in AML associated with increased genomic instability. TP53 mutations are linked to complex cytogenetic abnormalities, advanced age, chemoresistance, and poor outcomes, highlighting the need for optimal treatment strategies. Recent advancements in AML research and targeted therapies offer new possibilities in treating patients with TP53 mutations.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Chronic Lymphocytic Leukemia: Prognostic Factors at Presentation in a Resource-Limited Center

Kaladada Ibitrokoemi Korubo et al.

Summary: This study aimed to determine prognostic factors easily available to hematologists in low- or medium-income countries in the setting of chronic lymphocytic leukemia (CLL). The results showed that WBC count and absolute lymphocyte count >100 x 10(9)/L were significant poor prognostic markers. Patients who received chemotherapy had a better overall survival.

JCO GLOBAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries

Steven T. Bird et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia

Ke Shi et al.

CANCER MEDICINE (2020)

Add to Collection

Review Pharmacology & Pharmacy

Targeting p53 in chronic lymphocytic leukemia

Riccardo Moia et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2020)

Add to Collection

Meeting Abstract Hematology

Increase in Mortality and Second Neoplasms in Chronic Lymphocytic Leukemia with Pro/Pro Genotype of TP53 Codon 72

Martin Cabero-Becerra et al.

BLOOD (2020)

Add to Collection

Article Oncology

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients

Yan Qin et al.

CANCER MANAGEMENT AND RESEARCH (2020)

Add to Collection

Review Oncology

Mutant p53 in Cancer Progression and Targeted Therapies

Gaoyang Zhu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Review Oncology

Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods

Maria de Lourdes L. F. Chauffaille et al.

HEMATOLOGY TRANSFUSION AND CELL THERAPY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Evaluation of TP53 Codon 72, P21 Codon 31, and MDM2 SNP309 Polymorphisms in Iranian Patients with Acute Lymphocytic Leukemia

Ahmad Lotfi Garavand et al.

REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis

Xin Huang et al.

BIOSCIENCE REPORTS (2019)

Add to Collection

Article Hematology

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

Michael Hallek

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection

Article Cell Biology

Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas

Lawrence A. Donehower et al.

CELL REPORTS (2019)

Add to Collection

Article Oncology

Association of the TP53 rs1042522 C>G polymorphism and hepatoblastoma risk in Chinese children

Tianyou Yang et al.

JOURNAL OF CANCER (2019)

Add to Collection

Article Hematology

Impact Of TP53 Gene Promoter Methylation On Chronic Lymphocytic Leukemia Pathogenesis And Progression

Waleed Haji Saeed et al.

JOURNAL OF BLOOD MEDICINE (2019)

Add to Collection

Article Hematology

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek et al.

BLOOD (2018)

Add to Collection

Review Hematology

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics

Elias Campo et al.

HAEMATOLOGICA (2018)

Add to Collection

Review Hematology

Current prognostic and predictive factors in follicular lymphoma

Marc Sorigue et al.

ANNALS OF HEMATOLOGY (2018)

Add to Collection

Review Oncology

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force

R. Stauder et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

A. Stengel et al.

LEUKEMIA (2017)

Add to Collection

Article Medicine, Research & Experimental

The Transactivation Domains of the p53 Protein

Nitin Raj et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Chronic lymphocytic leukaemia

Thomas J. Kipps et al.

NATURE REVIEWS DISEASE PRIMERS (2017)

Add to Collection

Article Oncology

Significant association of TP53 Arg72Pro polymorphism in susceptibility to differentiated thyroid cancer

Mosin S. Khan et al.

CANCER BIOMARKERS (2015)

Add to Collection

Article Multidisciplinary Sciences

Increased Risk of Cutaneous Melanoma Associated with p53 Arg72Pro Polymorphism

Peiliang Geng et al.

PLOS ONE (2015)

Add to Collection

Article Oncology

TP53 Polymorphisms in Sporadic North Indian Breast Cancer Patients

Sarika Sharma et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)

Add to Collection

Article Oncology

TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia

Hua-Jie Dong et al.

MEDICAL ONCOLOGY (2014)

Add to Collection

Article Multidisciplinary Sciences

Evaluating the Association between p53 Codon 72 Arg>Pro Polymorphism and Risk of Ovary Cancer: A Meta-Analysis

Mohammed A. A. Alqumber et al.

PLOS ONE (2014)

Add to Collection

Review Oncology

Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis

Yu Lu et al.

TUMOR BIOLOGY (2014)

Add to Collection

Review Oncology

From pathogenesis to treatment of chronic lymphocytic leukaemia

Thorsten Zenz et al.

NATURE REVIEWS CANCER (2010)

Add to Collection

Article Oncology

p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia

Onoshua Lahiri et al.

CANCER GENETICS AND CYTOGENETICS (2007)

Add to Collection

Article Oncology

Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia

Geothy Kochethu et al.

LEUKEMIA RESEARCH (2006)

Add to Collection

Article Oncology

InB-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis -: art. no. 105

I Sturm et al.

BMC CANCER (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.